• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Public Health . Protocol of a Population-Based Prospective COVID-19 Cohort Study Munich, Germany (KoCo19)

tetano

Editor, Senior Moderator
BMC Public Health


. 2020 Jun 30;20(1):1036.
doi: 10.1186/s12889-020-09164-9.
Protocol of a Population-Based Prospective COVID-19 Cohort Study Munich, Germany (KoCo19)

Katja Radon[SUP] 1 2 [/SUP], Elmar Saathoff[SUP] 3 4 [/SUP], Michael Pritsch[SUP] 3 [/SUP], Jessica Michelle Guggenb?hl Noller[SUP] 3 [/SUP], Inge Kroidl[SUP] 3 4 [/SUP], Laura Olbrich[SUP] 3 [/SUP], Verena Thiel[SUP] 3 [/SUP], Max Diefenbach[SUP] 3 [/SUP], Friedrich Riess[SUP] 3 [/SUP], Felix Forster[SUP] 5 [/SUP], Fabian Theis[SUP] 6 7 [/SUP], Andreas Wieser[SUP] 3 8 [/SUP], Michael Hoelscher[SUP] 9 3 4 [/SUP], KoCo19 collaboration group


Collaborators, AffiliationsExpand
Free PMC article

Abstract

Background: Due to the SARS-CoV-2 pandemic, public health interventions have been introduced globally in order to prevent the spread of the virus and avoid the overload of health care systems, especially for the most severely affected patients. Scientific studies to date have focused primarily on describing the clinical course of patients, identifying treatment options and developing vaccines. In Germany, as in many other regions, current tests for SARS-CoV2 are not conducted on a representative basis and in a longitudinal design. Furthermore, knowledge about the immune status of the population is lacking. Nonetheless, these data are needed to understand the dynamics of the pandemic and hence to appropriately design and evaluate interventions. For this purpose, we recently started a prospective population-based cohort in Munich, Germany, with the aim to develop a better understanding of the state and dynamics of the pandemic.
Methods: In 100 out of 755 randomly selected constituencies, 3000 Munich households are identified via random route and offered enrollment into the study. All household members are asked to complete a baseline questionnaire and subjects ≥14 years of age are asked to provide a venous blood sample of ≤3 ml for the determination of SARS-CoV-2 IgG/IgA status. The residual plasma and the blood pellet are preserved for later genetic and molecular biological investigations. For twelve months, each household member is asked to keep a diary of daily symptoms, whereabouts and contacts via WebApp. If symptoms suggestive for COVID-19 are reported, family members, including children < 14 years, are offered a pharyngeal swab taken at the Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, for molecular testing for SARS-CoV-2. In case of severe symptoms, participants will be transferred to a Munich hospital. For one year, the study teams re-visits the households for blood sampling every six weeks.
Discussion: With the planned study we will establish a reliable epidemiological tool to improve the understanding of the spread of SARS-CoV-2 and to better assess the effectiveness of public health measures as well as their socio-economic effects. This will support policy makers in managing the epidemic based on scientific evidence.

Keywords: COVID-19; Coronavirus infections/epidemiology; Enzyme-linked Immunosorbent assay; Geographic information systems; Models, economic; Pandemics; Panel study; Socio-economic factors; Spatial analysis; Stress, psychological.
 
Back
Top Bottom